FY1Q profit beat expectations, orders grew 56%, target price raised to ¥9,900

Overview

Harmonic Drive Systems announced FY3/27 first-quarter results for the period ended June 2026. Sales were broadly in line with expectations, while operating profit and net profit exceeded market consensus by 34% and 20%, respectively, mainly benefiting from revenue growth, higher capacity utilization and strong operating leverage. Orders grew 56% year-on-year, led by demand for semiconductor equipment and medical equipment, while AI robot orders also maintained growth. The company raised its full-year earnings targets, and Deutsche Bank accordingly increased its earnings forecasts and maintained its Buy rating.

Core views

In the short term, rapid growth in semiconductor and medical equipment orders and an order-to-sales ratio rising to about 1.45x provide support for subsequent revenue; margin improvement indicates that the recovery has transmitted from the revenue side to the profit side. Over the medium to long term, HDS has advantages in manufacturing technology, global capacity layout and a non-China supply chain in the field of harmonic reducers for humanoid robots, while commercialization of actuators may further increase value per unit. Aerospace and semiconductor equipment also represent additional sources of growth, but continued weakness in China, the recovery pace of traditional industrial robots and the commercialization progress of humanoid robots still need to be monitored.

Analysis framework

The report combines quarterly results versus market consensus, end-market and regional order analysis, management guidance revisions, segment earnings forecasts and sum-of-the-parts valuation. Mature base businesses are valued using forward P/E, the aerospace business using P/S, and the humanoid robot business is valued based on 2030 market size, market share and profit assumptions, then discounted back to 2027.

Methodology notes

• Valuation methodologySum-of-the-parts valuation

  Separately assess and aggregate the value of the base business, aerospace and humanoid robot businesses.

  The target price of ¥9,900 consists of ¥4,866 per share for the base business, ¥542 per share for the aerospace business, and ¥4,492 per share for the humanoid robot business.

• Relative valuationP/E valuation

  Use one-year forward P/E to assess the mature base business.

  The base business uses an approximately 90x one-year forward P/E, above the long-term average of about 78x, because the company has entered an upcycle.

• Relative valuationPS valuation

  Use a revenue multiple to assess the aerospace business.

  The aerospace business uses a 6.5x P/S multiple on FY26E revenue, corresponding to a value of about ¥542 per share.

• Scenario and long-term valuationHumanoid robot market share model

  Estimate long-term value based on 2030 global humanoid robot production volume, per-unit component demand and HDS market share.

  The base case assumes global humanoid robots reach 1 million units in 2030, HDS has 15% and 3% shares in reducers and rotary actuators, respectively, and the 2030 value is discounted back to 2027.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Harmonic Drive Systems (6324.T)

  Report subject and Buy-rated recommendation target

  Strengths

  Leading harmonic reducer manufacturing technology and a strong position in the global robot reducer market; production footprint covering Japan, the United States and Germany; diversified growth sources from semiconductors, medical, aerospace and humanoid robots; improved capacity utilization brings strong profit elasticity.

  Weaknesses

  China orders continue to decline and there may be share loss; the traditional industrial robot business is still affected by industry cycles; the company has historically missed some medium-term targets.

  Comparison

  The report states that HDS's reducer revenue in 2025 was about 5x that of Leaderdrive and views it as a natural non-China supplier for humanoid robot customers; its humanoid robot revenue forecast is compared with Leaderdrive.

  Risks

  Slow recovery in traditional industrial robots, humanoid robot commercialization falling short of expectations, reducer competition or technological substitution, price competition suppressing margins, and risk of valuation contraction.

Key data

• FY1Q sales¥16.7bn, up 24% year-on-yearAbout 2% above market consensus, broadly in line with expectations.
• FY1Q operating profit¥1.8bn, up 1402% year-on-year34% above market consensus.
• FY1Q net profit¥1.3bnNet loss of ¥38mn in the same period last year, 20% above market consensus.
• FY1Q operating margin11%Up about 10 percentage points year-on-year and about 3 percentage points quarter-on-quarter.
• Consolidated order growthUp 56% year-on-yearSignificantly accelerated from 16% in FY25, with an order-to-sales ratio of about 1.45x.
• Semiconductor equipment ordersUp 111% year-on-yearOne of the main drivers of order growth this quarter.
• Medical equipment ordersUp 179% year-on-yearMay include a one-off large order.
• AI robot ordersAbout ¥1.25bn, up about 24% to 25% year-on-yearLong-term growth prospects remain favorable.
• Regional order performanceNorth America grew 126%, Japan grew 52%, Europe grew 37%, China declined 23%China has declined for four consecutive quarters, with its share of group sales falling to about 6%.
• Full-year targets after upward revisionSales ¥74.5bn, operating profit ¥8.5bn, net profit ¥6.0bnUp 25%, 40% and 273% year-on-year, respectively.
• Humanoid robot revenue forecastFY3/27E of ¥4.2bn, FY3/28E of ¥9.0bnExpected to account for approximately 6% and 10% of group revenue, respectively.
• Target price¥9,900Previously ¥8,500, about 38.8% above the reference share price of ¥7,130.

Impact & implications

The results and guidance upgrade reinforce the view that HDS is in an earnings recovery and order upcycle. If semiconductor capex continues to expand, medical orders convert smoothly and humanoid robot customer adoption accelerates, revenue growth and higher capacity utilization may continue to amplify profit elasticity. Diversified manufacturing footprints in the United States, Japan and Germany may also enable HDS to benefit from demand for non-China robot supply chains. However, the current valuation already embeds high growth expectations, and long-term humanoid robot valuation is relatively sensitive to assumptions on market size, market share and discount rates.

Risks

• The global traditional industrial robot market recovers more slowly than expected.
• The humanoid robot market develops slowly, causing order and revenue forecasts to fail to materialize.
• Competition among harmonic reducer manufacturers intensifies, or other transmission solutions form technological substitutes.
• Price competition intensifies, weakening margin recovery and operating leverage.
• China orders have declined for four consecutive quarters, and regional share may continue to be lost.
• The high growth in medical equipment orders may include a one-off large order, making sustainability uncertain.
• The target price is relatively sensitive to high P/E multiples and assumptions on 2030 humanoid robot market size and share.
• The company has historically failed to achieve some medium-term operating targets, and execution risk still needs attention.

What to watch

• Whether semiconductor and medical equipment orders can continue to convert into sales revenue.
• Subsequent changes in consolidated order growth, order-to-sales ratio and operating margin.
• Whether the decline in China orders, sales mix and market share stabilizes.
• Whether U.S. monthly capacity can increase to 10,000 to 15,000 units by the end of 2026.
• Validation progress with Japanese humanoid robot customers and whether actuators can be commercialized within about 1.5 years.
• Achievement of the raised FY3/27 full-year sales, operating profit and net profit targets.
• Changes in global wafer fab equipment capex and the aerospace business revenue share.
• Customer nominations, market share and competitive landscape for humanoid robot reducers and rotary actuators.